Lyfgenia

Pharma

Vertex gains FDA expansion of Casgevy to those ages 2 and older

The FDA has granted a label expansion for children ages 2 and up to receive Vertex's gene therapy Casgevy for sickle cell disease or beta thalassemia.

Kevin Dunleavy Jul 6, 2026 11:30am

UPDATED: Most expensive drugs in the US in 2025

Aug 11, 2025 3:00am

bluebird investors get on board with sale to Carlyle, SK Capital

May 30, 2025 11:50am

Once valued at $10B, struggling bluebird bio sold for $29M

Feb 21, 2025 10:56am

Bluebird bio lays off 25% of workforce

Sep 24, 2024 10:19am

Bluebird Bio CEO snares 24 million pay package as gene therapy advance

Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia

Aug 14, 2024 12:07pm